Discharge prescription for ischemic stroke patients

Stroke is a major public health issue: it affects 120 000 people in France each year. The yearly recurrence rate is thought to reach 8 percent. Secondary prevention of stroke is thus crucial and focuses on controlling vascular risk factors most often associated with antiplatelet agents. Therapeutic...

Full description

Saved in:
Bibliographic Details
Published in:Revue neurologique 2005-07, Vol.161 (6-7), p.738
Main Authors: Rosolacci, T, Neuville, V
Format: Article
Language:fre
Subjects:
Atrial Fibrillation - drug therapy
Brain Ischemia - complications
Brain Ischemia - drug therapy
Constriction, Pathologic
Drug Prescriptions
Fibrinolytic Agents - therapeutic use
Hormones - therapeutic use
Humans
Patient Discharge
Stroke - complications
Stroke - drug therapy
Stroke - prevention & control
Vascular Diseases - drug therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Stroke is a major public health issue: it affects 120 000 people in France each year. The yearly recurrence rate is thought to reach 8 percent. Secondary prevention of stroke is thus crucial and focuses on controlling vascular risk factors most often associated with antiplatelet agents. Therapeutic objectives are set depending on the individual's global cardiovascular risk. The PROGRESS study has shown the relevance of systematic blood pressure lowering using an angiotensin-converting-enzyme inhibitor (perindopril) in combination with a diuretic (indapamide) in secondary prevention of stroke, including in normotensive patients. If possible, blood pressure should be below 130/85 mmHg. Statins are indicated in stroke patients with hypercholesterolemia, coronary heart disease, diabetes mellitus or carotid stenosis, the target LDL-cholesterol level being below 1 g/L (2.58 mmol/L). There is a wide consensus on treating patients with symptomatic carotid stenoses > or = 70 percent by thrombo-endarterectomy and stroke associated with atrial fibrillation by anticoagulants. Management should be global and include changes in dietary behavior, tobacco and/or alcohol withdrawal, and regular exercising. Patient-specific therapeutic education should be offered in order to improve compliance.
ISSN:0035-3787